The Pharma Letter | FDA to Investigate Diabetes Drug Saxagliptin for Possible Heart Failure Risk U.S. News & World Report TUESDAY, Feb. 11, 2014 (HealthDay News) -- The U.S. Food and Drug Administration announced Tuesday that it will investigate possible links between the diabetes drug saxagliptin and a heightened risk for heart failure among users. In a statement, the ... FDA Investigating Heart Failure Risk Linked To Onglyza FDA to review heart failure risk associated with saxagliptin FDA to review heart failure risk with AstraZeneca diabetes drug |
